EP0581805A1 - Nouvelles pyridazines - Google Patents

Nouvelles pyridazines

Info

Publication number
EP0581805A1
EP0581805A1 EP92908818A EP92908818A EP0581805A1 EP 0581805 A1 EP0581805 A1 EP 0581805A1 EP 92908818 A EP92908818 A EP 92908818A EP 92908818 A EP92908818 A EP 92908818A EP 0581805 A1 EP0581805 A1 EP 0581805A1
Authority
EP
European Patent Office
Prior art keywords
amino
compounds
salts
difluoromethoxy
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92908818A
Other languages
German (de)
English (en)
Inventor
Hermann Amschler
Christian Schudt
Volker Figala
Dieter Flockerzi
Ulrich Kilian
Rolf Beume
Richard Riedel
Manfrid Eltze
Guido Hanauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Byk Gulden Lomberg Chemische Fabrik GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chemische Fabrik GmbH filed Critical Byk Gulden Lomberg Chemische Fabrik GmbH
Publication of EP0581805A1 publication Critical patent/EP0581805A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Definitions

  • the invention relates to 3-amino-6-aryl-pyridazines, processes for their preparation, their use and medicaments containing them.
  • the compounds according to the invention are used in the pharmaceutical industry for the manufacture of medicaments.
  • the invention relates to 3-amino-6-aryl-pyridazines of the general formula I (see the attached formula sheet), in which one of the substituents R1 and R2 is methoxy, difluoroethoxy or ethoxy, and the other 1-5C-alkoxy, 4-7C -Cycloalkoxy, 3-7C-cycloalkylmethoxy, 3-5C-alkenyloxy or 1-4C-polyfluoroalkoxy means, X means amino, and their salts with acids and their N-oxides.
  • 1-5C-Alkoxy is straight-chain or branched.
  • Exemplary 1-5C-alkoxy radicals are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec.-butoxy, tert.-butoxy, n-pentyloxy and isopentyl - oxy and the 2,2-dimethylpropoxy residue.
  • 3-4C alkoxy is preferred.
  • 4-7C-Cycloalkoxy stands for example for cyclobutyloxy, cyclopentyloxy, cyclohexyloxy and cycloheptyloxy, of which cyclopentyloxy is preferred.
  • 3-7C-Cycloalkylmethoxy stands for example for cyclopropylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy, cyclohexylmethoxy and cycloheptylmethoxy, of which cyclopropylmethoxy and cyclobutylmethoxy are preferred.
  • j-5C-Alkenyloxy is straight or branched. The double bond of al enyloxy does not start from the carbon atom that binds to the oxygen atom.
  • Examples of 3-5C-alkenyloxy radicals are buten-2-yloxy, the alloxy and the methylyloxy radical.
  • 1-5C-Alkoxy is preferred over 3-5C-alkenyloxy.
  • 1-4C-Polyfluoroalkoxy is understood to mean straight-chain or branched 1-4C-alkoxy in which at least 2 hydrogen atoms have been replaced by fluorine.
  • Straight chain 1-3C-alkoxy in which at least 2 hydrogen atoms are replaced by fluorine is preferred.
  • Preferred 1-4C-polyfluoroalkoxy groups are trifluoromethoxy, 1,1,2,2-tetrafluoroethoxy and in particular difluoromethoxy and 2,2,2-trifluoroethoxy.
  • Amino is understood to mean the NH group.
  • Suitable salts for compounds of the formula I are preferably all acid addition salts. Particular mention should be made of the pharmacologically tolerable salts of the inorganic and organic acids usually used in galenics. Pharmacologically incompatible salts, which may initially be obtained as process products in the preparation of the compounds according to the invention on an industrial scale, are converted into pharmacologically acceptable salts by processes known to the person skilled in the art.
  • Suitable as such are, for example, water-soluble and water-insoluble acid addition salts, such as the hydrochloride, hydrobromide, hydroiodide, phosphate, nitrate, sulfate, acetate, citrate, gluconate, benzoate, hibenzate, Fe ⁇ dizoat, butyrate, sulfosalicylate, maleate, laurate, malate, fumarate Succinate, oxalate, tartrate, amsonate, embonate, metembonate, stearate, tosilate, 3-hydroxy-2-naphthoate or mesilate.
  • water-soluble and water-insoluble acid addition salts such as the hydrochloride, hydrobromide, hydroiodide, phosphate, nitrate, sulfate, acetate, citrate, gluconate, benzoate, hibenzate, Fe ⁇ dizoat, butyrate, sulfosalicylate, maleate, la
  • N-oxides of the compounds of the formula I can be described by the general formula I * (see formula sheet), in which R1, R2 and X have the meanings indicated above.
  • the N-oxides of the 3-amino-6-aryl-pyridazines according to the invention can exist as tautomeric forms.
  • a proton of the 3-amino group can to migrate this group and the oxygen in the 2-position of the pyridazine ring.
  • the other tautomer is also to be understood.
  • An embodiment (embodiment a) of the invention are 3-amino-6-arylpyridazines of the general formula I, in which
  • R2 is 1-4C-alkoxy, 4-7C-cycloalkoxy, 3-6C-cycloalkylmethoxy, 3-4C-alkenyloxy or 1--2C-polyfluoroalkoxy and X is amino, and their salts with acids and their N-oxides.
  • Another embodiment (embodiment b) of the invention are 3-amino-6-aryl-pyridazines of the general formula I, in which
  • Rl is 3-4C-alkoxy, 4-7C-cycloalkoxy, 3-6C-cycloalkylmethoxy, 3-4C-alkenyloxy or l-2C-polyfluoroalkoxy
  • R2 is methoxy, difluoromethoxy or ethoxy
  • X is amino, and their salts with acids and their N -Oxides.
  • Preferred compounds according to the invention are those of the formula I in which one of the substituents R1 and R2 is methoxy, difluoromethoxy or ethoxy and the other is 1-4C-alkoxy, 4-7C-cycloalkoxy, 3-6C-cycloalkylmethoxy or 1-2C-polyfluoroalkoxy and X means amino, and their salts with acids and their N-oxides.
  • Preferred representatives of embodiment a are those in which R2 is 1-4C-A1k-oxy or 1-2C-polyfluoroalkoxy.
  • Preferred representatives of embodiment b are those in which Rl is 3-4C-A1k-oxy, 4-7C-cycloalkoxy, 3-6C-cycloalkylmethoxy or I-2C-polyfluoroalkoxy.
  • the configuration b is preferred over the configuration a.
  • Particularly preferred compounds according to the invention are those of the formula I in which R 1 is 2-4C-alkoxy, cyclopentyloxy, cyclopropyl methoxy, cyclobutyl methoxy, difluoromethoxy or 2,2,2-trifluoroethoxy, R 2 is methoxy, Ethoxy or difluoromethoxy means and X means amino, and their pharmaceutically acceptable salts with acids and their N-oxides.
  • the invention further relates to a process for the preparation of the 3-amino-6-aryl-pyridazines of the general formula I, in which Rl, R2 and X have the meaning given above, and their salts with acids and their N-oxides, which is characterized in that is that one
  • the compounds I obtained according to a), b), c) or d) are subsequently converted into their salts, or if desired the compounds I are subsequently released from the salts of the compounds I obtained or that if desired, the compounds I obtained according to a), b), c) or d) are subsequently converted into their N-oxides.
  • the method according to variant a) is carried out in a manner familiar to the person skilled in the art.
  • Halogen atoms especially chlorine and bromine, are particularly suitable as leaving groups Y which can be displaced nucleophilically.
  • the reaction with ammonia takes place, for example, according to EA Steck et al. , J.Heterocycl .Chem.12, 1009, 1975 in an alcohol such as ethanol, ethylene glycol or polyethylene glycol 400, preferably with excess ammonia at temperatures from 150 to 200 ° C, preferably at 180 to 200 ° C, in one Autoclave is being worked.
  • the 3-hydrazino-pyridazines of formula III are hydrogenated in a manner known per se to the person skilled in the art.
  • the compounds III are hydrogenated in an alcohol, preferably methanol, with the addition of a hydrogenation catalyst such as Raney nickel or palladium / carbon at temperatures between 20 and 65 ° C., preferably at room temperature.
  • a hydrogenation catalyst such as Raney nickel or palladium / carbon at temperatures between 20 and 65 ° C., preferably at room temperature.
  • the compounds III can be subjected to catalytic transfer hydrogenolysis, as described, for example, by G. Brieger and TJNestrick in Chem. Rev. 74, 567 (1974).
  • the compounds III are first converted into their salts with a mineral acid, such as hydrochloric or sulfuric acid, and then in an alcohol, such as, for example, methanol or ethanol, with palladium / carbon and a hydrogen donor, such as cyclohexene, cyclohexadiene, formic acid or hydrogenated ammonium formate at temperatures of 20 to 80 ⁇ C.
  • a mineral acid such as hydrochloric or sulfuric acid
  • an alcohol such as, for example, methanol or ethanol
  • a hydrogen donor such as cyclohexene, cyclohexadiene, formic acid or hydrogenated ammonium formate at temperatures of 20 to 80 ⁇ C.
  • hydrolysis of phosphazenes IV in process variant c) is carried out in a manner known per se, preferably in dilute mineral acids, such as hydrochloric acid or sulfuric acid, or in aqueous organic acids, such as acetic acid or formic acid.
  • the process according to process variant d) is also carried out in a manner known per se, the debenzylation of the benzyl compounds V preferably taking place under the conditions of catalytic transfer hydrogenolysis, for which purpose the compounds V, for example, in a mixture of glacial acetic acid / conc. Hydrochloric acid and cyclohexene can be debenzylated in the presence of palladium / carbon as a catalyst.
  • Acid addition salts are obtained by dissolving the free base in a suitable solvent, e.g. in a chlorinated hydrocarbon, such as methylene chloride or chloroform, or a low molecular weight aliphatic alcohol (ethanol, isopropanol) which contains the desired acid or to which the desired acid is subsequently added.
  • a chlorinated hydrocarbon such as methylene chloride or chloroform
  • a low molecular weight aliphatic alcohol ethanol, isopropanol
  • the salts are obtained by filtration, reprecipitation, precipitation with a non-solvent for the addition salt or by evaporation of the solvent. Salts obtained can by alkalization, for example with aqueous ammonia solution, are converted into the free bases, which in turn can be converted into acid addition salts. In this way, pharmacologically unacceptable acid addition salts can be converted into pharmacologically acceptable acid addition salts.
  • Suitable oxidants are all reagents commonly used for N-oxidation, in particular hydrogen peroxide or (if necessary prepared in situ) organic and inorganic peroxy compounds, such as e.g. Peroxyacetic acid, trifluoroperoxyacetic acid, 3,5-dinitroperoxybenzoic acid, peroxy alic acid, m-chloroperoxybenzoic acid or potassium per anganate.
  • the compounds of formula II are known or they can be prepared by known processes, e.g. are described in EP-A-393500.
  • the 3-hydrazino-pyridazines of the formula III are obtained, for example, by compounds of the formula II corresponding to CG. Wermuth et al. , J.Med. Chem., Q, 239, 1987, with hydrazine hydrate at 100'C, preferably in an inert solvent, e.g. in an alcohol, such as 1-butanol, or without a solvent.
  • the phosphazenes of the formula IV are also obtained starting from compounds of the formula II, which are initially described in accordance with Th. Cap et al. , Synthesis 1989. 666, converted to tetrazolo [1,5-b] pyridazines by the technique of phase transfer catalysis (see J. Dockx, Synthesis 1973, 441).
  • the compounds II are, for example, in a hydrocarbon, such as toluene or xylene, or in an ether, such as dioxane, or a ketone, such as 2-methyl-4-pentanone (isobutyl methyl ketone), or an N, N- disubstituted acid amide, such as dimethylformamide or N-methylpyrrolidone under anhydrous conditions, preferably in the presence of 0.1 to 1.0 mol of the phase transfer catalyst at temperatures from 50 to ⁇ :..
  • uu "C in particular from 80 to 150 ⁇ C, preferably at the boiling point of the Lö ⁇ sungsmittels, reacted with at least 1 mole of alkali metal azide come ferkatalysatoren
  • Suitable examples are crown ethers , quaternary phosphonium salts and especially quaternary ammonium salts, such as tetrabutylammonium chloride.
  • the tetrazolo [1,5-b] pyridazines obtained are then heated at 80 to 150 ° C., in particular at 80, by heating with at least 1 mol of triphenylphosphine in an inert solvent, such as benzene, toluene, xylene or chlorobenzene to 135 ⁇ C, preferably at the boiling point of the solvent, converted into the phosphazenes IV.
  • an inert solvent such as benzene, toluene, xylene or chlorobenzene
  • the compounds of formula V are prepared from the corresponding compounds II with benzylamine by heating, preferably without a solvent at from 140 to 200 Temperatu ⁇ ren ⁇ C, preferably prepared at 180 to 190 ° C.
  • Mp Means melting point
  • Sdp Means boiling point
  • the 3-amino-6-aryl-pyridazines according to the invention and their salts and N-oxides have valuable pharmacological properties which make them commercially usable. They are characterized above all by those properties that make them appear suitable for the therapy of respiratory diseases of various origins. In particular, inflammatory and allergen-induced bronchial diseases can be treated due to the anti-inflammatory and broncholytic activity of the compounds according to the invention. In addition, the compounds according to the invention are notable for low toxicity, a wide therapeutic range and the absence of significant side effects.
  • broncholytic and anti-inflammatory activity of the compounds according to the invention enables their use in human and veterinary medicine, where they are used for the treatment and prophylaxis of diseases which are based on diseases of the bronchi.
  • diseases which are based on diseases of the bronchi.
  • acute and chronic obstructive respiratory diseases of various origins bronchitis, allergic bronchitis, bronchial asthma
  • Another object of the invention is therefore a method for the treatment of mammals, including humans, who are suffering from one of the above-mentioned diseases.
  • the method is characterized in that the sick mammal is administered a therapeutically effective and pharmacologically compatible amount of one or more of the compounds according to the invention.
  • the invention further relates to the compounds according to the invention for use in the treatment and / or prophylaxis of diseases which are based on diseases of the bronchi.
  • the invention also relates to the use of the compounds according to the invention for the production of medicaments which are used for the treatment and / or prophylaxis of diseases which are based on diseases of the bronchi.
  • the invention furthermore relates to medicaments for the treatment and / or prophylaxis of diseases which are based on diseases of the bronchi and which contain one or more of the compounds according to the invention and / or their pharmacologically tolerable salts.
  • the medicaments according to the invention are produced by methods known per se, reference being made, for example, to the explanations in European patent 163 965 with regard to the preparations, dosages, dosage forms, etc.
  • 3-amino-6-aryl-pyridazines according to the invention and their salts and N-oxides are furthermore outstandingly suitable for the treatment of dermatoses.
  • proliferative, inflammatory and allergic skin diseases are mentioned as dermatoses.
  • the compounds of the formula I can be used to prevent and treat the following skin diseases: psoriasis vulgaris, toxic and allergic contact dermatitis, atopic dermatitis, seborrheic dermatitis, follicular and areal pyoderma, endogenous and exogenous acne, rosacea and acne other proliferative, inflammatory and allergic skin diseases.
  • the invention thus furthermore relates to the use of compounds of the formula I and their pharmacologically tolerable salts and N-oxides for the treatment of such individuals who are suffering from dermatoses.
  • the compounds of the formula I are used in particular in the form of those medicaments which are suitable for topical application.
  • suitable pharmaceutical formulations include, for example, powders, emulsions, suspensions, sprays, oils, ointments, fatty ointments, creams, pastes, gels or solutions in which the active substance content is advantageously between 0.1 and 99%.
  • the person skilled in the art is familiar with the auxiliaries which are suitable for the desired pharmaceutical formulations on the basis of his specialist knowledge.
  • active substance carriers for example antioxidants, dispersants, emulsifiers, preservatives, solubilizers or permeation promoters can be used.
  • 3-amino-6-aryl-pyridazines to the invention are as well as their salts and N-oxides, 'the released (in particular by interleukins and mainly by tumor necrosis factor) as well as leukotrienes by certain cytokines for the prevention and treatment of theimiszustän- , where the treatment of the septic shock or the toxic shock syndrome should be particularly emphasized.
  • 3-amino-6-aryl-pyridazines according to the invention and their salts and N-oxides for the prevention and treatment of allergic and / or chronic incorrect reactions in the area of the upper respiratory tract (throat, nose) and the adjacent regions (paranasal sinuses, eye) , such as allergic rhinitis / sinusitis, chronic rhinitis / sinusitis, allergic conjunctivitis and nasal polyps.
  • the guinea pig chain was tested in vitro as follows:
  • test substance in a cumulative semi-logarithmic increase
  • Concentration for example 1x10 + 2x10 + 7x10 + 2x10 etc. mol / 1:
  • Table 1 shows the values -lg [EC 5Q ] and the quotients from the EC ⁇ o values for theophylline and the substance investigated. The values found show a great superiority of the compounds according to the invention over theophylline in terms of bronchospasmolytic activity.
  • bronchospasmolytic effect was also determined using the model "Hista-induced bronchospasm in anesthetized guinea pigs":
  • test substances were administered intravenously (IV) and / or intrajejunal (IV).
  • Guinea pigs 250 - 350 g are sealed in a sealed plexiglass cylinder (volume 5 l) twice before the administration of the substance with an acetylcholine mist (0.06% in 0.9% sodium chloride solution; ultrasonic nebulizer Heyer Use 77) at intervals of 20 minutes after the administration of the substance. set out.
  • the time from the beginning of the nebulization until the onset of significant breathing efforts is measured and referred to as latency.
  • test substances are administered orally by means of a pharyngeal tube (dose 100 ⁇ mol / kg, volume 1 ml / kg, suspension medium 4% methocel suspension in 0.9% sodium chloride solution).
  • the latency is 2 minutes.
  • the test substance is administered orally using a pharyngeal tube (standard dose 100 ⁇ ol, volume 1 ml of 4% methocel suspension in 0.9% sodium chloride solution / kg).
  • a pharyngeal tube standard dose 100 ⁇ ol, volume 1 ml of 4% methocel suspension in 0.9% sodium chloride solution / kg.
  • the animals are again exposed to the acetylcholine mist and the latency times are measured.
  • An extension of the latency to at least three times the length is regarded as a protective effect.
  • PDE IV high affinity cAMP-PDE cannot be inhibited by cGMP, Rolipra-sensitive
  • PDE III high affinity cAMP-PDE inhibitable by cGMP
  • the PDE inhibition of the compounds according to the invention was therefore determined on a PDE III isolated from human thrombocytes or from human neutrophilic polymorphonuclear cells (PMN's) and from PDE IV isolated from the dog trachea.
  • the phosphodiesterases III and IV are according to Polson et al., Bioche. Phar acol .21, 3403-3406 (1982) chromatographically isolated.
  • the substances are dissolved in DMSO and further diluted. 2.1 .mu.l of each are introduced from a series of solutions diluted up to 100 times and 212 .mu.l of reaction mixture are added.
  • the reaction mixture contains Hepes (100 mmol / 1), DTE (5 mmol / 1), MgCl 2 (5 mmol / 1), CaCl 2 (10 ⁇ mol / 1), BSA fraction V 0.5 mg / ml, cAMP 0, 5 mol / 1, 2.8 to 3 H-cAMP 250,000 cpm / ml (0.3 uCi / ml, SA 33.5 Ci / mmol), SV (snake venom) 25 ug / 212 ul Testan ⁇ set).
  • Table 4 shows the negative logarithms of the IC ⁇ Q values found and the quotients from the IC 50 values of the substances according to the invention determined for PDE III and PDE IV inhibition.
  • the substances according to the invention inhibit PDE IV significantly more specifically and more strongly than theophylline.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Des composés de formule (I) dans laquelle R1, R2 et X ont les significations données dans la description, ainsi que leurs sels et leurs oxydes de N, sont de nouvelles substances actives pour le traitement d'affections bronchitiques et de dermites.
EP92908818A 1991-04-26 1992-04-21 Nouvelles pyridazines Withdrawn EP0581805A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CH1255/91 1991-04-26
CH125591 1991-04-26
CH125691 1991-04-26
CH1256/91 1991-04-26
CH199791 1991-07-05
CH1997/91 1991-07-05

Publications (1)

Publication Number Publication Date
EP0581805A1 true EP0581805A1 (fr) 1994-02-09

Family

ID=27172829

Family Applications (2)

Application Number Title Priority Date Filing Date
EP92106743A Pending EP0510562A1 (fr) 1991-04-26 1992-04-21 Pyridazines
EP92908818A Withdrawn EP0581805A1 (fr) 1991-04-26 1992-04-21 Nouvelles pyridazines

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP92106743A Pending EP0510562A1 (fr) 1991-04-26 1992-04-21 Pyridazines

Country Status (4)

Country Link
US (1) US5449676A (fr)
EP (2) EP0510562A1 (fr)
AU (1) AU1574892A (fr)
WO (1) WO1992019602A1 (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9212673D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
US5622977A (en) * 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
GB9226830D0 (en) * 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
AU687087B2 (en) * 1993-07-02 1998-02-19 Takeda Gmbh Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
DE69433594T2 (de) * 1993-12-22 2004-08-05 Celltech R&D Ltd., Slough Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
GB9326173D0 (en) * 1993-12-22 1994-02-23 Celltech Ltd Chemical compounds and process
IL112235A (en) * 1994-01-03 2000-06-29 Acea Pharm Inc 1,4-dihydro-pyrido¬2,3-b¾pyrazine-2,3-dione (5 or 8) oxide derivatives and pharmaceutical compositions containing them
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412573D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412571D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) * 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
JP4373497B2 (ja) 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
WO1998028281A1 (fr) 1996-12-23 1998-07-02 Celltech Therapeutics Limited Derives polycyclique fondus de 2-aminopyrimidine, leur preparation et leur utilisation comme inhibiteurs de proteine tyrosine-kinase
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
AU753576B2 (en) * 1997-12-15 2002-10-24 Altana Pharma Ag Dihydrobenzofurans
US20020006961A1 (en) * 1999-05-14 2002-01-17 Katz Stanley E. Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
PT1212089E (pt) 1999-08-21 2006-08-31 Altana Pharma Ag Combinacao sinergica de roflumilast e salmeterol
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
KR100874791B1 (ko) 2001-05-29 2008-12-18 바이엘 쉐링 파마 악티엔게젤샤프트 Ｃｄｋ-억제 피리미딘, 그의 제조방법 및 약제로서의 용도
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP2006522151A (ja) 2003-04-01 2006-09-28 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 不妊症におけるホスホジエステラーゼ阻害剤
WO2004099158A1 (fr) * 2003-04-30 2004-11-18 Ricerca Biosciences, Llc. N-oxydes monocycliques utilises comme antagonistes des proteines bcl-2
CA3089569C (fr) 2007-06-04 2023-12-05 Synergy Pharmaceuticals Inc. Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
US8122510B2 (en) * 2007-11-14 2012-02-21 Bank Of America Corporation Method for analyzing and managing unstructured data
MY158927A (en) * 2008-06-12 2016-11-30 Janssen Pharmaceutica Nv Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h4 receptor
EP2321341B1 (fr) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
ES2550667T3 (es) * 2010-02-18 2015-11-11 Vtv Therapeutics Llc Derivados de fenilheteroarilo y métodos de uso de los mismos
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN108676076A (zh) 2011-03-01 2018-10-19 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
EP2970384A1 (fr) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
RS65632B1 (sr) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe
WO2015021358A2 (fr) 2013-08-09 2015-02-12 Dominique Charmot Composés et procédés d'inhibition du transport de phosphate
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT78566B (de) * 1983-05-11 1986-07-17 Byk Gulden Lomberg Chem Fab Pyridazinone ihre herstellung und verwendung pyridazinone enthaltende arzneimittel
DK159431C (da) * 1984-05-10 1991-03-18 Byk Gulden Lomberg Chem Fab 6-phenyl-3(2h)-pyridazinoner, fremgangsmaade til fremstilling deraf, laegemidler indeholdende disse samt anvendelse af forbindelserne til fremstilling af laegemidler
DE3517617A1 (de) * 1985-05-15 1986-11-20 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Neue pyridaziniumverbindungen, verfahren zu deren herstellung und diese enthaltende fungizide und algizide mittel
US4791110A (en) * 1985-06-14 1988-12-13 Eli Lilly And Company Fungicidal pyridazines
JPH04504576A (ja) * 1989-04-17 1992-08-13 ビイク　グルデン　ロンベルク―ヒェーミッシェ　ファブリーク　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング 新規アリールピリダジン、その製造、使用およびこれを含有する医薬品

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9219602A1 *

Also Published As

Publication number Publication date
EP0510562A1 (fr) 1992-10-28
WO1992019602A1 (fr) 1992-11-12
AU1574892A (en) 1992-12-21
US5449676A (en) 1995-09-12

Similar Documents

Publication Publication Date Title
EP0581805A1 (fr) Nouvelles pyridazines
EP0469013B1 (fr) Arylpyridazines, leur preparation, leur utilisation et medicaments les contenant
DE69432087T2 (de) 6-Amino-purinderivate mit PDE-IV inhibierender Wirkung
DE60005493T2 (de) Pyrimido[6,1-a]isochinolinonderivate
EP0163965B1 (fr) Pyridazinones, leur préparation et leur utilisation, médicaments contenant des pyridazinones
DE2934747C2 (fr)
DE60128457T2 (de) 1,5-DISUBSTITUIERTE 3,4-DIHYDRO-1H-4,5-DöPYRIMIDIN-2-ON-VERBINDUNGEN UND IHRE VERWENDUNG IN DER BEHANDLUNG VON DURCH CSBP/P38 KINASE BEEINFLUSSTEN KRANKHEITEN
DE3750913T2 (de) Karbostyrilderivate, Verfahren zu ihrer Herstellung, diese enthaltende pharmazeutische Zusammensetzungen und ihre Verwendung.
EP0509398B1 (fr) Quinoxalines, procédé pour leur préparation et leur utilisation
EP0888313B1 (fr) Derives de 2,3-benzodiazepine et leur utilisation comme inhibiteurs de recepteurs d'ampa
DE68918406T2 (de) Xanthinderivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate.
EP1087946A1 (fr) Arylalcanoylpyridazines
EP0327800A2 (fr) 6-Phényldihydro-3(2H)-pyridazinones substituées, procédé pour leur préparation et médicaments contenant ces composés
EP0657166B1 (fr) Composition contenant un quinoxaline et un nucléosid
EP0125636B1 (fr) Pyridazinones, leur préparation et usage, médicaments contenant ces pyridazinones
DE4424714A1 (de) Neue chemische Verbindung, ihre Herstellung und ihre Verwendung als Arnzneistoff
DE102005017286B3 (de) Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
JPH06506674A (ja) 新規ピリダジン
DE19629378A1 (de) Neue Triazolopurine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE3320102C2 (fr)
DE2804949A1 (de) Substituierte tetrazolverbindungen
DE3049959C2 (fr)
DE60202969T2 (de) Substituierte alkylaminopyridazinonderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
DE2913295A1 (de) 4-oxo-4h-pyrido eckige klammer auf 1,2-a eckige klammer zu pyrimidin-3-n- (1h-tetrazol-5-yl)carboxamide, verfahren zu deren herstellung und pharmazeutisches mittel
DE3874465T2 (de) 1,2,3,4-tetrahydroisochonoline als antiarrhythmische mittel.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

17P Request for examination filed

Effective date: 19931022

RBV Designated contracting states (corrected)

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL PT SE

XX Miscellaneous (additional remarks)

Free format text: VERBUNDEN MIT 92106743.5/0510562 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) DURCH ENTSCHEIDUNG VOM 20.04.95.

17Q First examination report despatched

Effective date: 19970616

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19990803